Pharmacological treatment of schizophrenia and psychosis includes the use of antipsychotics, which act as orthosteric receptor antagonists/partial agonists of various GPCR targets, including dopamine receptor D2 and serotonin receptor 5HT1A. This evidence concerns the gene DRD2 and psychotic disorder.